UK firm Intelligent Fingerprinting has said the highly sensitive fluorescence measurement capabilities of its lateral flow technology could help to accelerate Covid-19 diagnostic testing at the point of care.
The company’s DSR-Plus analysis unit can detect specific drugs or their metabolites in the eccrine sweat collected from fingerprints. Combining this with a dedicated Covid-19 testing cartridges could potentially provide the basis for a test suitable for deployment at a range of locations.
Go deeper with GlobalData
Potential partners interested in this project are encouraged to contact Intelligent Fingerprinting executive chairman Philip Hand.
